Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
Insider exercise expanded his direct stake by 16% to 609,519 shares, bringing total beneficial ownership to ~760,000 shares valued at $22.8 million.
Overview
Director Christopher Viehbacher purchased 83,333 shares of Braveheart Bio, Inc. (NASDAQ:BRVE) at $18.00 per share on August 7, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($18.00); post-transaction value based on August 7, 2026 market close ($30.00).
Details
Braveheart Bio, Inc. is an early-stage biotechnology company headquartered in San Francisco with a market capitalization of $2.1 billion as of Aug. 7, 2026. The company is advancing a focused pipeline of cardiac myosin inhibitors designed to address unmet medical needs in the treatment of hypertrophic cardiomyopathy. As a pre-revenue clinical-stage entity, Braveheart Bio's value proposition centers on the clinical potential and differentiated mechanism of action of its lead therapeutic candidate.
Source
Originally published at www.fool.com.